商品名:プラムリンチド
同義語:トリプロアミル
順序:Lys-c[Cys-Asn-Thr-Ala-Thr-Cys]-Ala-Thr-Gln-Arg-Leu-Ala-Asn-Phe-Leu -Val-His-Ser-Ser-Asn-Asn-Phe-Gly-Pro-Ile-Leu-Pro-Pro-Thr-Asn-Val- Gly -Ser-Asn-Thr-Tyr-NH2
CAS:151126-32-8
MF:C171H267N51O53S2.C2H4O2.H2O
MW:4027.49
EINECS:1592732-453-0
プラムリンチド (trade name Symlin) is an injectable amylin analogue drug for diabetes (both type 1 そして 2), developed by Amylin Pharmaceuticals (now a wholly owned subsidiary of AstraZeneca).Pramlintide is sold as an acetate salt.
Pramlintide is an analogue of amylin, a small peptide hormone that is released into the bloodstream by the β cells of the pancreas along with insulin after a meal.Like insulin, amylin is completely absent in individuals with Type I diabetes.
In synergy with endogenous amylin, pramlintide aids in the regulation of blood glucose by slowing gastric emptying, promoting satiety via hypothalamic receptors (different receptors than for GLP-1), and inhibiting inappropriate secretion of glucagon, a catabolic hormone that opposes the effects of insulin and amylin. Pramlintide also has effects in raising the acute first-phase insulin response threshold following a meal.
Both a reduction in glycated hemoglobin and weight loss have been shown in insulin-treated patients with type 2 diabetes taking pramlintide as an adjunctive therapy.
